Moya Bio
Tumor Immune Conditioning Agents
Company Overview
Snapshot
Founded in December 2017 by Yifat Merbl, PhD, Moya Bio operated with 1–10 employees. The company raised $3 million across one disclosed funding round from two investors. In December 2017, Moya Bio began developing a pipeline of modulators for the FAT10 regulatory pathway for cancer treatment.
Business overview
Moya Bio is a Health Tech & Life Sciences company focused on developing a novel class of tumor immune conditioning agents. The company's core technology involves inhibitors of the FAT10 pathway, designed to enhance the impact of immunotherapy by sensitizing tumors to immune-mediated cytotoxicity. This approach aims to benefit additional patient populations by increasing T-cell infiltration into the tumor microenvironment and inhibiting tumor growth. Moya Bio's platform supports a synergistic effect with immune checkpoint inhibitors, targeting the pharmaceuticals and biotechnology sectors within the life sciences market globally.
Log in to access full profile ›Company Intelligence Q&A
- What is Moya Bio's primary focus?
- Moya Bio is focused on developing a novel class of tumor immune conditioning agents to enhance the efficacy of cancer immunotherapy.
- Who founded Moya Bio?
- Moya Bio was founded by Yifat Merbl, PhD, in December 2017.
- What is the core technology behind Moya Bio's approach?
- Moya Bio's core technology involves inhibitors of the FAT10 pathway, which are designed to increase the impact of immunotherapy by sensitizing tumors to immune-mediated cytotoxicity.
- What is the current operational status of Moya Bio?
- Moya Bio is currently non-active and ceased to operate in November 2024.
- What was a key early development for Moya Bio?
- In December 2017, Moya Bio began developing a pipeline of modulators of the FAT10 regulatory pathway for cancer treatment.